Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1

Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe disease after re-infection by multiple variants of concern (VOC), including Omicron, despite the lack of a strong neutralizing response to these...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1266829
Main Authors Balinsky, Corey A., Jiang, Le, Jani, Vihasi, Cheng, Ying, Zhang, Zhiwen, Belinskaya, Tatyana, Qiu, Qi, Long, Tran Khanh, Schilling, Megan A., Jenkins, Sarah A., Corson, Karen S., Martin, Nicholas J., Letizia, Andrew G., Hontz, Robert D., Sun, Peifang
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 2023
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2023.1266829

Cover

Loading…
Abstract Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe disease after re-infection by multiple variants of concern (VOC), including Omicron, despite the lack of a strong neutralizing response to these variants. We compared antibody responses in serum samples collected from mRNA-1273 (Moderna) vaccinated subjects to identify mechanisms of immune escape and cross-protection. Using pseudovirus constructs containing domain-specific amino acid changes representative of Omicron BA.1, combined with domain competition and RBD-antibody depletion, we showed that RBD antibodies were primarily responsible for virus neutralization and variant escape. Antibodies to NTD played a less significant role in antibody neutralization but acted along with RBD to enhance neutralization. S2 of Omicron BA.1 had no impact on neutralization escape, suggesting it is a less critical domain for antibody neutralization; however, it was as capable as S1 at eliciting IgG3 responses and NK-cell mediated, antibody-dependent cell cytotoxicity (ADCC). Antibody neutralization and ADCC activities to RBD, NTD, and S1 were all prone to BA.1 escape. In contrast, ADCC activities to S2 resisted BA.1 escape. In conclusion, S2 antibodies showed potent ADCC function and resisted Omicron BA.1 escape, suggesting that S2 contributes to cross-protection against Omicron BA.1. In line with its conserved nature, S2 may hold promise as a vaccine target against future variants of SARS-CoV-2.
AbstractList Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe disease after re-infection by multiple variants of concern (VOC), including Omicron, despite the lack of a strong neutralizing response to these variants. We compared antibody responses in serum samples collected from mRNA-1273 (Moderna) vaccinated subjects to identify mechanisms of immune escape and cross-protection. Using pseudovirus constructs containing domain-specific amino acid changes representative of Omicron BA.1, combined with domain competition and RBD-antibody depletion, we showed that RBD antibodies were primarily responsible for virus neutralization and variant escape. Antibodies to NTD played a less significant role in antibody neutralization but acted along with RBD to enhance neutralization. S2 of Omicron BA.1 had no impact on neutralization escape, suggesting it is a less critical domain for antibody neutralization; however, it was as capable as S1 at eliciting IgG3 responses and NK-cell mediated, antibody-dependent cell cytotoxicity (ADCC). Antibody neutralization and ADCC activities to RBD, NTD, and S1 were all prone to BA.1 escape. In contrast, ADCC activities to S2 resisted BA.1 escape. In conclusion, S2 antibodies showed potent ADCC function and resisted Omicron BA.1 escape, suggesting that S2 contributes to cross-protection against Omicron BA.1. In line with its conserved nature, S2 may hold promise as a vaccine target against future variants of SARS-CoV-2.
Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe disease after re-infection by multiple variants of concern (VOC), including Omicron, despite the lack of a strong neutralizing response to these variants. We compared antibody responses in serum samples collected from mRNA-1273 (Moderna) vaccinated subjects to identify mechanisms of immune escape and cross-protection. Using pseudovirus constructs containing domain-specific amino acid changes representative of Omicron BA.1, combined with domain competition and RBD-antibody depletion, we showed that RBD antibodies were primarily responsible for virus neutralization and variant escape. Antibodies to NTD played a less significant role in antibody neutralization but acted along with RBD to enhance neutralization. S2 of Omicron BA.1 had no impact on neutralization escape, suggesting it is a less critical domain for antibody neutralization; however, it was as capable as S1 at eliciting IgG3 responses and NK-cell mediated, antibody-dependent cell cytotoxicity (ADCC). Antibody neutralization and ADCC activities to RBD, NTD, and S1 were all prone to BA.1 escape. In contrast, ADCC activities to S2 resisted BA.1 escape. In conclusion, S2 antibodies showed potent ADCC function and resisted Omicron BA.1 escape, suggesting that S2 contributes to cross-protection against Omicron BA.1. In line with its conserved nature, S2 may hold promise as a vaccine target against future variants of SARS-CoV-2.Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe disease after re-infection by multiple variants of concern (VOC), including Omicron, despite the lack of a strong neutralizing response to these variants. We compared antibody responses in serum samples collected from mRNA-1273 (Moderna) vaccinated subjects to identify mechanisms of immune escape and cross-protection. Using pseudovirus constructs containing domain-specific amino acid changes representative of Omicron BA.1, combined with domain competition and RBD-antibody depletion, we showed that RBD antibodies were primarily responsible for virus neutralization and variant escape. Antibodies to NTD played a less significant role in antibody neutralization but acted along with RBD to enhance neutralization. S2 of Omicron BA.1 had no impact on neutralization escape, suggesting it is a less critical domain for antibody neutralization; however, it was as capable as S1 at eliciting IgG3 responses and NK-cell mediated, antibody-dependent cell cytotoxicity (ADCC). Antibody neutralization and ADCC activities to RBD, NTD, and S1 were all prone to BA.1 escape. In contrast, ADCC activities to S2 resisted BA.1 escape. In conclusion, S2 antibodies showed potent ADCC function and resisted Omicron BA.1 escape, suggesting that S2 contributes to cross-protection against Omicron BA.1. In line with its conserved nature, S2 may hold promise as a vaccine target against future variants of SARS-CoV-2.
Author Cheng, Ying
Qiu, Qi
Letizia, Andrew G.
Jenkins, Sarah A.
Hontz, Robert D.
Long, Tran Khanh
Zhang, Zhiwen
Corson, Karen S.
Sun, Peifang
Martin, Nicholas J.
Schilling, Megan A.
Balinsky, Corey A.
Jiang, Le
Belinskaya, Tatyana
Jani, Vihasi
Author_xml – sequence: 1
  givenname: Corey A.
  surname: Balinsky
  fullname: Balinsky, Corey A.
– sequence: 2
  givenname: Le
  surname: Jiang
  fullname: Jiang, Le
– sequence: 3
  givenname: Vihasi
  surname: Jani
  fullname: Jani, Vihasi
– sequence: 4
  givenname: Ying
  surname: Cheng
  fullname: Cheng, Ying
– sequence: 5
  givenname: Zhiwen
  surname: Zhang
  fullname: Zhang, Zhiwen
– sequence: 6
  givenname: Tatyana
  surname: Belinskaya
  fullname: Belinskaya, Tatyana
– sequence: 7
  givenname: Qi
  surname: Qiu
  fullname: Qiu, Qi
– sequence: 8
  givenname: Tran Khanh
  surname: Long
  fullname: Long, Tran Khanh
– sequence: 9
  givenname: Megan A.
  surname: Schilling
  fullname: Schilling, Megan A.
– sequence: 10
  givenname: Sarah A.
  surname: Jenkins
  fullname: Jenkins, Sarah A.
– sequence: 11
  givenname: Karen S.
  surname: Corson
  fullname: Corson, Karen S.
– sequence: 12
  givenname: Nicholas J.
  surname: Martin
  fullname: Martin, Nicholas J.
– sequence: 13
  givenname: Andrew G.
  surname: Letizia
  fullname: Letizia, Andrew G.
– sequence: 14
  givenname: Robert D.
  surname: Hontz
  fullname: Hontz, Robert D.
– sequence: 15
  givenname: Peifang
  surname: Sun
  fullname: Sun, Peifang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38077368$$D View this record in MEDLINE/PubMed
BookMark eNp9Ul1vFCEUnZgaW2v_gA-GR19mBe7AwuO6qbaxtklXfSXMcKdh3YF1YI37l_orZT9sjA8SEi7ccw7hcF5WJyEGrKrXjE4AlH7X-2HYTDjlMGFcSsX1s-qMSdnUwHlz8ld9Wl2ktKRlNBoAxIvqFBSdTkGqs-pxFrJvo_OYSI5kwYmLg_WBxJ4sZveLeh6_1Zyktf-OZD3GjKVX5ufocAyWDPe3M_LTdp0PNqMjadMuscupFCnvdOxBf1s7XGNwGDK5_UQ6XK3qAZ3fk3Y70m1zzPGX73zeEvtQuCmTu8F3Ywzk_WzCXlXPe7tKeHFcz6uvHy6_zK_qm7uP1_PZTd01DHKtVE9ZrwQoQNtTCY4y2wDVSFvJUHKmOIqulY3QGqZTAdC6VmhQrLSchvPq-qDrol2a9egHO25NtN7sD-L4YOyYfbdCwxFEL-mUo6INlcx2WlhFrWCNdsyKovX2oFWs-7HBlM3g0-65NmDcJMM15VoAh6ZA3xyhm7Y483Txn78qAH4AFEdSGrF_gjBqdpkw-0yYXSbMMROFpP4hFX9t9jHk0frV_6i_Afj0u6k
CitedBy_id crossref_primary_10_3390_vaccines13030262
crossref_primary_10_1002_jmv_29585
crossref_primary_10_3389_fimmu_2025_1535014
Cites_doi 10.1126/science.abn8652
10.1001/jamanetworkopen.2023.10650
10.1093/infdis/jiad054
10.1101/2022.04.30.489997
10.15585/mmwr.mm7112e1
10.1126/scitranslmed.abm2311
10.7554/eLife.06054
10.1126/science.abn7760
10.1038/s41467-022-33378-7
10.1128/CVI.00230-14
10.1016/j.it.2019.01.005
10.1038/s41467-020-16638-2
10.1038/s41392-021-00759-1
10.1016/j.ijid.2021.11.040
10.1002/eji.202149470
10.1126/science.abn8863
10.1038/s41541-021-00393-6
10.1038/s41586-021-04385-3
10.1038/s41598-018-36972-2
10.1016/j.vaccine.2021.05.063
10.3389/fimmu.2021.637651
10.1016/j.isci.2022.105202
10.1126/scitranslmed.abi9215
10.3201/eid2607.200841
10.4049/jimmunol.174.4.2185
10.1056/NEJMc2119912
10.1016/j.jviromet.2017.06.007
10.1038/s41591-021-01377-8
10.1038/s41586-021-04386-2
10.1371/journal.pone.0248007
10.3389/fimmu.2020.576622
10.1126/science.abj3321
10.1016/S0022-1759(98)00170-7
10.1016/j.cell.2022.06.005
10.1097/QAD.0000000000001200
10.1016/j.celrep.2021.109929
10.1080/22221751.2020.1815591
10.1002/smll.202200836
10.1016/j.cell.2021.03.028
10.1038/s41591-021-01678-y
10.1016/j.lana.2022.100297
10.1016/j.chom.2021.06.001
10.1038/s41423-021-00778-6
10.1073/pnas.2107249118
10.7554/eLife.83710.sa2
10.1016/j.celrep.2021.110114
10.1038/s41467-021-21968-w
10.1128/mBio.02473-21
10.1016/j.cell.2020.02.058
10.1038/s41577-020-0402-6
10.4049/jimmunol.1201574
10.3389/fimmu.2021.737083
10.1016/j.chom.2021.03.005
10.1016/j.jim.2016.11.005
10.1128/spectrum.01837-22
10.1038/s41586-022-04399-5
10.1056/NEJMc2212117
10.1038/nm.3443
10.1016/j.lfs.2020.118056
10.1126/science.abb2507
10.1126/science.abm3425
10.1089/08892220260387940
10.1073/pnas.2217590120
10.1093/infdis/jiac319
10.1001/jamanetworkopen.2022.54777
10.1038/s41591-020-0913-5
10.1016/j.cell.2020.05.015
10.1038/s41586-020-2598-9
10.1016/j.xcrm.2021.100329
ContentType Journal Article
Copyright Copyright © 2023 Balinsky, Jiang, Jani, Cheng, Zhang, Belinskaya, Qiu, Long, Schilling, Jenkins, Corson, Martin, Letizia, Hontz and Sun.
Copyright_xml – notice: Copyright © 2023 Balinsky, Jiang, Jani, Cheng, Zhang, Belinskaya, Qiu, Long, Schilling, Jenkins, Corson, Martin, Letizia, Hontz and Sun.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOA
DOI 10.3389/fimmu.2023.1266829
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_2e35f6072e804061ac95a80a5149d1a5
38077368
10_3389_fimmu_2023_1266829
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
CGR
CUY
CVF
ECM
EIF
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
ID FETCH-LOGICAL-c413t-88f01f85383eaf063d01a4309e0b61e62182e5cb64599377533bdb59381218d93
IEDL.DBID DOA
ISSN 1664-3224
IngestDate Wed Aug 27 01:27:53 EDT 2025
Thu Jul 10 23:25:06 EDT 2025
Wed Feb 19 02:11:02 EST 2025
Thu Apr 24 23:01:15 EDT 2025
Tue Jul 01 03:33:40 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Omicron BA.1
SARS-CoV-2
Moderna mRNA vaccine
ADCC
IgG subclass
S2
Language English
License Copyright © 2023 Balinsky, Jiang, Jani, Cheng, Zhang, Belinskaya, Qiu, Long, Schilling, Jenkins, Corson, Martin, Letizia, Hontz and Sun.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c413t-88f01f85383eaf063d01a4309e0b61e62182e5cb64599377533bdb59381218d93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/2e35f6072e804061ac95a80a5149d1a5
PMID 38077368
PQID 2902953234
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_2e35f6072e804061ac95a80a5149d1a5
proquest_miscellaneous_2902953234
pubmed_primary_38077368
crossref_primary_10_3389_fimmu_2023_1266829
crossref_citationtrail_10_3389_fimmu_2023_1266829
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-00-00
PublicationDateYYYYMMDD 2023-01-01
PublicationDate_xml – year: 2023
  text: 2023-00-00
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Haslwanter (B67) 2021; 12
Chen (B13) 2020; 20
Tuekprakhon (B27) 2022; 185
Li (B10) 2021; 18
Tejedor Vaquero (B49) 2021; 12
Morrison (B57) 2017; 248
Excler (B34) 2014; 21
Yates (B51) 2021; 2
Izadi (B53) 2023; 120
Cao (B26) 2022; 608
Wang (B64) 2021; 12
Jegaskanda (B40) 2013; 190
Mannar (B24) 2022; 375
Ma (B55) 2022; 18
Damelang (B52) 2019; 40
Silva (B62) 2023; 12
Frey (B44) 1998; 221
Hagemann (B41) 2022; 52
Zolla-Pazner (B33) 2016; 30
Kleanthous (B8) 2021; 6
Wei (B31) 2023; 6
Yu (B16) 2021; 6
Kallolimath (B54) 2021; 118
Cao (B22) 2022; 602
Sun (B42) 2017; 441
Duan (B2) 2020; 11
Kaplonek (B48) 2022
Tenforde (B46) 2022; 71
Pajon (B47) 2022; 386
McCallum (B19) 2022; 375
Amanat (B39) 2020; 26
Sun (B29) 2023; 228
Stowe (B32) 2022; 13
Sternberg (B3) 2020; 257
Prompetchara (B56) 2021; 16
DiLillo (B35) 2014; 20
Hsieh (B66) 2021; 37
Petro (B36) 2015; 4
Zhou (B63) 2022; 14
Yin (B21) 2022; 375
Poh (B9) 2020; 11
Gilbert (B5) 2022; 375
Banks (B58) 2002; 18
McCallum (B69) 2021; 184
Wrapp (B4) 2020; 367
Braun (B15) 2020; 587
Petersen (B37) 2022; 114
Pinto (B11) 2021; 373
Skarbinski (B45) 2022; 12
Sun (B60) 2022; 25
Menegale (B30) 2023; 6
Khoury (B7) 2021; 27
Shah (B18) 2021; 12
Carreno (B23) 2022; 602
Grifoni (B14) 2020; 181
Sun (B43) 2019; 9
Gomez-Roman (B59) 2005; 174
Walls (B1) 2020; 181
Cameroni (B20) 2022; 602
Tauzin (B61) 2021; 29
Earle (B6) 2021; 39
Kato (B38) 2022; 227
Yi (B12) 2020; 9
Farkash (B50) 2021; 37
Hachmann (B28) 2022; 387
VanBlargan (B25) 2022; 28
Vangeti (B65) 2022; 10
Cerutti (B68) 2021; 29
Nisreen (B17) 2020; 26
References_xml – volume: 375
  year: 2022
  ident: B19
  article-title: Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
  publication-title: Science
  doi: 10.1126/science.abn8652
– volume: 6
  year: 2023
  ident: B30
  article-title: Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and meta-analysis
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2023.10650
– volume: 228
  year: 2023
  ident: B29
  article-title: Antibody responses to the SARS-CoV-2 ancestral strain and omicron variants in moderna mRNA-1273 vaccinated active-duty U.S. Navy sailors and marines
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiad054
– volume: 608
  year: 2022
  ident: B26
  article-title: BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
  publication-title: Nature
  doi: 10.1101/2022.04.30.489997
– volume: 71
  year: 2022
  ident: B46
  article-title: Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death - United States, March 2021-January 2022
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm7112e1
– year: 2022
  ident: B48
  article-title: mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.abm2311
– volume: 4
  year: 2015
  ident: B36
  article-title: Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease
  publication-title: Elife
  doi: 10.7554/eLife.06054
– volume: 375
  year: 2022
  ident: B24
  article-title: SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex
  publication-title: Science
  doi: 10.1126/science.abn7760
– volume: 13
  start-page: 5736
  year: 2022
  ident: B32
  article-title: Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-33378-7
– volume: 21
  year: 2014
  ident: B34
  article-title: Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines
  publication-title: Clin Vaccine Immunol
  doi: 10.1128/CVI.00230-14
– volume: 40
  start-page: 197
  year: 2019
  ident: B52
  article-title: Role of IgG3 in infectious diseases
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2019.01.005
– volume: 11
  start-page: 2806
  year: 2020
  ident: B9
  article-title: Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-16638-2
– volume: 6
  start-page: 346
  year: 2021
  ident: B16
  article-title: Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-021-00759-1
– volume: 114
  year: 2022
  ident: B37
  article-title: Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2021.11.040
– volume: 52
  year: 2022
  ident: B41
  article-title: Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients
  publication-title: Eur J Immunol
  doi: 10.1002/eji.202149470
– volume: 375
  year: 2022
  ident: B21
  article-title: Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody
  publication-title: Science
  doi: 10.1126/science.abn8863
– volume: 6
  start-page: 128
  year: 2021
  ident: B8
  article-title: Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-021-00393-6
– volume: 602
  year: 2022
  ident: B22
  article-title: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
  publication-title: Nature
  doi: 10.1038/s41586-021-04385-3
– volume: 9
  start-page: 1109
  year: 2019
  ident: B43
  article-title: NK cells activated through antibody-dependent cell cytotoxicity and armed with degranulation/IFN-gamma production suppress antibody-dependent enhancement of dengue viral infection
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-36972-2
– volume: 39
  year: 2021
  ident: B6
  article-title: Evidence for antibody as a protective correlate for COVID-19 vaccines
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2021.05.063
– volume: 12
  year: 2021
  ident: B18
  article-title: The case for S2: the potential benefits of the S2 subunit of the SARS-CoV-2 spike protein as an immunogen in fighting the COVID-19 pandemic
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.637651
– volume: 25
  start-page: 105202
  year: 2022
  ident: B60
  article-title: Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern
  publication-title: iScience
  doi: 10.1016/j.isci.2022.105202
– volume: 14
  year: 2022
  ident: B63
  article-title: A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.abi9215
– volume: 26
  year: 2020
  ident: B17
  article-title: Severe acute respiratory syndrome Coronavirus 2–specific antibody responses in coronavirus disease 2019 patients
  publication-title: Emerg Infect Dis J
  doi: 10.3201/eid2607.200841
– volume: 174
  year: 2005
  ident: B59
  article-title: Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251
  publication-title: J Immunol
  doi: 10.4049/jimmunol.174.4.2185
– volume: 386
  year: 2022
  ident: B47
  article-title: SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2119912
– volume: 248
  start-page: 7
  year: 2017
  ident: B57
  article-title: Antibody-dependent NK cell degranulation as a marker for assessing antibody-dependent cytotoxicity against pandemic 2009 influenza A(H1N1) infection in human plasma and influenza-vaccinated transchromosomic bovine intravenous immunoglobulin therapy
  publication-title: J Virol Methods
  doi: 10.1016/j.jviromet.2017.06.007
– volume: 27
  year: 2021
  ident: B7
  article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01377-8
– volume: 602
  year: 2022
  ident: B20
  article-title: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
  publication-title: Nature
  doi: 10.1038/s41586-021-04386-2
– volume: 16
  year: 2021
  ident: B56
  article-title: DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice
  publication-title: PloS One
  doi: 10.1371/journal.pone.0248007
– volume: 11
  year: 2020
  ident: B2
  article-title: The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.576622
– volume: 373
  year: 2021
  ident: B11
  article-title: Broad betacoronavirus neutralization by a stem helix-specific human antibody
  publication-title: Science
  doi: 10.1126/science.abj3321
– volume: 221
  start-page: 35
  year: 1998
  ident: B44
  article-title: A statistically defined endpoint titer determination method for immunoassays
  publication-title: J Immunol Methods
  doi: 10.1016/S0022-1759(98)00170-7
– volume: 185
  start-page: 2422
  year: 2022
  ident: B27
  article-title: Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
  publication-title: Cell
  doi: 10.1016/j.cell.2022.06.005
– volume: 30
  year: 2016
  ident: B33
  article-title: Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates
  publication-title: AIDS
  doi: 10.1097/QAD.0000000000001200
– volume: 37
  start-page: 109929
  year: 2021
  ident: B66
  article-title: Stabilized coronavirus spike stem elicits a broadly protective antibody
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2021.109929
– volume: 9
  year: 2020
  ident: B12
  article-title: Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population
  publication-title: Emerg Microbes Infect
  doi: 10.1080/22221751.2020.1815591
– volume: 18
  start-page: e2200836
  year: 2022
  ident: B55
  article-title: SARS-CoV-2 spike stem protein nanoparticles elicited broad ADCC and robust neutralization against variants in mice
  publication-title: Small
  doi: 10.1002/smll.202200836
– volume: 184
  start-page: 2332
  year: 2021
  ident: B69
  article-title: N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
  publication-title: Cell
  doi: 10.1016/j.cell.2021.03.028
– volume: 28
  year: 2022
  ident: B25
  article-title: An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01678-y
– volume: 12
  start-page: 100297
  year: 2022
  ident: B45
  article-title: Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study
  publication-title: Lancet Reg Health Am
  doi: 10.1016/j.lana.2022.100297
– volume: 29
  start-page: 1137
  year: 2021
  ident: B61
  article-title: A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.06.001
– volume: 18
  year: 2021
  ident: B10
  article-title: A novel linear and broadly neutralizing peptide in the SARS-CoV-2 S2 protein for universal vaccine development
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-021-00778-6
– volume: 118
  year: 2021
  ident: B54
  article-title: Highly active engineered IgG3 antibodies against SARS-CoV-2
  publication-title: Proc Natl Acad Sci U.S.A.
  doi: 10.1073/pnas.2107249118
– volume: 12
  year: 2023
  ident: B62
  article-title: Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses
  publication-title: Elife
  doi: 10.7554/eLife.83710.sa2
– volume: 37
  start-page: 110114
  year: 2021
  ident: B50
  article-title: Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2021.110114
– volume: 12
  start-page: 1715
  year: 2021
  ident: B64
  article-title: A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-21968-w
– volume: 12
  year: 2021
  ident: B67
  article-title: A combination of receptor-binding domain and N-terminal domain neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
  publication-title: mBio
  doi: 10.1128/mBio.02473-21
– volume: 181
  start-page: 281
  year: 2020
  ident: B1
  article-title: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.058
– volume: 20
  year: 2020
  ident: B13
  article-title: T cell responses in patients with COVID-19
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-0402-6
– volume: 190
  year: 2013
  ident: B40
  article-title: Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1201574
– volume: 12
  year: 2021
  ident: B49
  article-title: The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.737083
– volume: 29
  start-page: 819
  year: 2021
  ident: B68
  article-title: Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.03.005
– volume: 441
  start-page: 24
  year: 2017
  ident: B42
  article-title: NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients
  publication-title: J Immunol Methods
  doi: 10.1016/j.jim.2016.11.005
– volume: 10
  start-page: e0183722
  year: 2022
  ident: B65
  article-title: Serum Fc-mediated monocyte phagocytosis activity is stable for several months after SARS-CoV-2 asymptomatic and mildly symptomatic infection
  publication-title: Microbiol Spectr
  doi: 10.1128/spectrum.01837-22
– volume: 602
  year: 2022
  ident: B23
  article-title: Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
  publication-title: Nature
  doi: 10.1038/s41586-022-04399-5
– volume: 387
  year: 2022
  ident: B28
  article-title: Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2212117
– volume: 20
  year: 2014
  ident: B35
  article-title: Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo
  publication-title: Nat Med
  doi: 10.1038/nm.3443
– volume: 257
  start-page: 118056
  year: 2020
  ident: B3
  article-title: Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2020.118056
– volume: 367
  year: 2020
  ident: B4
  article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
  publication-title: Science
  doi: 10.1126/science.abb2507
– volume: 375
  start-page: 43
  year: 2022
  ident: B5
  article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
  publication-title: Science
  doi: 10.1126/science.abm3425
– volume: 18
  year: 2002
  ident: B58
  article-title: Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS
  publication-title: AIDS Res Hum Retroviruses
  doi: 10.1089/08892220260387940
– volume: 120
  start-page: e2217590120
  year: 2023
  ident: B53
  article-title: Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization
  publication-title: Proc Natl Acad Sci U.S.A.
  doi: 10.1073/pnas.2217590120
– volume: 227
  year: 2022
  ident: B38
  article-title: Memory B cell development after asymptomatic or mild symptomatic SARS-CoV-2 infection
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiac319
– volume: 6
  start-page: e2254777
  year: 2023
  ident: B31
  article-title: Estimation of vaccine effectiveness of CoronaVac and BNT162b2 against severe outcomes over time among patients with SARS-CoV-2 omicron
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2022.54777
– volume: 26
  year: 2020
  ident: B39
  article-title: A serological assay to detect SARS-CoV-2 seroconversion in humans
  publication-title: Nat Med
  doi: 10.1038/s41591-020-0913-5
– volume: 181
  start-page: 1489
  year: 2020
  ident: B14
  article-title: Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
  publication-title: Cell
  doi: 10.1016/j.cell.2020.05.015
– volume: 587
  year: 2020
  ident: B15
  article-title: SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
  publication-title: Nature
  doi: 10.1038/s41586-020-2598-9
– volume: 2
  start-page: 100329
  year: 2021
  ident: B51
  article-title: Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity
  publication-title: Cell Rep Med
  doi: 10.1016/j.xcrm.2021.100329
SSID ssj0000493335
Score 2.3561027
Snippet Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against infection with the ancestral strain, and limits the presentation of severe...
SourceID doaj
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
Enrichment Source
StartPage 1266829
SubjectTerms ADCC
Antibody-Dependent Cell Cytotoxicity
COVID-19 - prevention & control
Humans
IgG subclass
Immunoglobulin G
Killer Cells, Natural
Moderna mRNA vaccine
Omicron BA.1
RNA, Messenger
SARS-CoV-2
Spike Glycoprotein, Coronavirus - genetics
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9QwFA7riuCLeHe8EcE36ZgmTad5EOkuLouyI-w4sm8lTdKlum3WaUd2_pK_0nPSzoDg-iT0oW1yeslJ-L4TkvMR8loEoaMEgpyqEhCg2DLKrHRRyY0WygHih0DxZJ4eL5OPZ_Jsj2zljsYG7P4a2qGe1HJ1Mb36sXkPA_4dRpyAt2-rumnWU9QBn8aANxlXN8hNQKYZSjmcjHT_28CGhRBy2Dtzjekf-BTS-F_PPQMGHd0ld0bySPPB2_fInmvvk1uDnOTmAfmVt31delwXSHtPF5xa30DkT31FF_npIjr0XyNOu8v6u6MhQQOUwTHooWnanM5z-lMbU7fAQC3t1iXO0nRwEnZZUT08fxNtpXN7Ov9Ece4_CjtQ0AivqNn0vvdXtQGOT_U52HY9_dzg4r-WHuTT-CFZHn34cngcjVoMkQGY66Msq1hcAbZnwukKeI1lsU4EU46VaexSTATvpCkxNw0wHgiCRGlLqYAQQJFV4hHZb33rnhBqNOM2BdoptEvkjGXWpSqVQtrUOsHshMRbDxRmTFSOehkXBQQs6LUieK1ArxWj1ybkzc7mckjT8c_aB-jYXU1MsR1u-NV5MY7Ygjshq5TNuMsYsh5tlNQZ08AwlY21nJBX225RwJDE1tWt8-uu4IpxJQUXyYQ8HvrL7lWY338m0uzp__iEZ-Q2_tYwI_Sc7PertXsBHKkvX4aO_xt0fQ0l
  priority: 102
  providerName: Scholars Portal
Title Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1
URI https://www.ncbi.nlm.nih.gov/pubmed/38077368
https://www.proquest.com/docview/2902953234
https://doaj.org/article/2e35f6072e804061ac95a80a5149d1a5
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1di9QwFA2yIPgifjt-EcE36WzaNJ3ksbu4LsqOsOPKvJU0SaWrbRebEecv-Su9N-mM-6K-CCW0TdOmvbecc0NyLiGveEh0lEOQ0zQcAhRbJ9IKl9SZ0Vw5QPwQKJ4ti9OL_N1arK-l-sI5YVEeOH64w8xx0RRskTnJEHy0UUJLpgHolU11UC8FzLsWTF1G3ss5F3GVDERh6rBpu24zx2Th8xRASQZO-RuJgmD_n1lmQJuTO-T2RBNpGbt3l9xw_T1yMyaO3N4nP8vet_WAMwCpH-gqo3boIManQ0NX5fkqOR4-JRkdr9ovjgYpBqiDLWY-07Q7X5b0uzam7YFrWjpuahyPGWEnrKeiOt5_m-yS5Hq6fE9xlD8Ja02wER5Rs_WDH360Btg81Z-h7ejphw6n-fX0qJynD8jFyZuPx6fJlHUhMQBoPpGyYWkDKC650w0wGMtSnXOmHKuL1BUo-e6EqVGFBrgNhDu8trVQAP1QZRV_SA76oXePCTWaZbYAgsm1y8WCSesKVQgubGEdZ3ZG0p0FKjNJkmNmjK8VhCZotSpYrUKrVZPVZuT1vs1VFOT469VHaNj9lSimHU6Ai1WTi1X_crEZeblziwp-Pvy6unfDZqwyxTIleMbzGXkU_WX_KFTyX_BCPvkfXXhKbuFrxbGfZ-TAf9u458CGfP0iOD6Ub9cplGe5_AUThQXC
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibodies+to+S2+domain+of+SARS-CoV-2+spike+protein+in+Moderna+mRNA+vaccinated+subjects+sustain+antibody-dependent+NK+cell-mediated+cell+cytotoxicity+against+Omicron+BA.1&rft.jtitle=Frontiers+in+immunology&rft.au=Corey+A.+Balinsky&rft.au=Le+Jiang&rft.au=Vihasi+Jani&rft.au=Ying+Cheng&rft.date=2023&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=14&rft_id=info:doi/10.3389%2Ffimmu.2023.1266829&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_2e35f6072e804061ac95a80a5149d1a5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon